Hideaki Nishihara¹, Kinya Matsuo², Satoru Morimoto³, Hideyuki Okano³ (1.Department of Neurotherapeutics, Yamaguchi University, Japan, 2.Department of Neurology, Yamaguchi University Graduate School of Medicine, Japan, 3.Department of Physiology, Keio University School of Medicine, Japan)

Motoki Miura^1,2, Fumika Sakaue^1,2, Hirokazu Matsuno^1,2, Kento Morita^1,2, Rintaro Hara^1,2, Takanori Yokota^1,2,3 (1.Department of Neurology and Neurological Science, Tokyo Medical and Dental University, Japan, 2.Center for Brain Integration Research (CBIR), Tokyo Medical and Dental University, Japan, 3.TMDU Nucleotide and Peptide Drug Discovery Center (TIDE), Tokyo Medical and Dental University, Japan)

Shintaro Hayashi^1,2, Ryo Yamasaki¹, Yuko Kobayakawa¹, Jun-ichi Kira^1,3,4, Noriko Isobe¹ (1.Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan, 2.Department of Neurology, Gunma Rehabilitation Hospital, Japan, 3.Translational Neuroscience Center, Graduate School of Medicine, and School of Pharmacy at Fukuoka, International University of Health and Welfare, Japan, 4.Department of Neurology, Brain and Nerve Center, Fukuoka Central Hospital, Japan)

Chen Jianmin^1,2, Chen Sheng^1,2, Lu Yingqian^1,2, Liu Changyun^1,2, Zou Zhangyu^1,2 (1.FUJIAN MEDICAL UNIVERSITY, China, 2.Fujian Medical University Union Hospital, China)